European Journal of Nuclear Medicine and Molecular Imaging

, Volume 34, Issue 2, pp 185–196

11C-acetate PET in the early evaluation of prostate cancer recurrence

Authors

    • Service of Nuclear MedicineUniversity Hospital of Geneva
  • Franz Buchegger
    • Service of Nuclear MedicineUniversity Hospital of Geneva
    • Service of Nuclear MedicineUniversity Hospital of Lausanne
  • Dmitri Soloviev
    • Service of Nuclear MedicineUniversity Hospital of Geneva
  • Habib Zaidi
    • Service of Nuclear MedicineUniversity Hospital of Geneva
  • Hansjoerg Vees
    • Service of Radiation OncologyUniversity Hospital of Geneva
  • Haleem G. Khan
    • Institute of Radiology Jean Violette
  • Alain Keller
    • Service of Nuclear MedicineUniversity Hospital of Geneva
  • Angelika Bischof Delaloye
    • Service of Nuclear MedicineUniversity Hospital of Lausanne
  • Osman Ratib
    • Service of Nuclear MedicineUniversity Hospital of Geneva
  • Raymond Miralbell
    • Service of Radiation OncologyUniversity Hospital of Geneva
    • Instituto Oncológico Teknon
Original article

DOI: 10.1007/s00259-006-0163-x

Cite this article as:
Albrecht, S., Buchegger, F., Soloviev, D. et al. Eur J Nucl Med Mol Imaging (2007) 34: 185. doi:10.1007/s00259-006-0163-x

Abstract

Purpose

The first aim of the study was to investigate the diagnostic potential of 11C-acetate PET in the early detection of prostate cancer recurrence. A second aim was the evaluation of early and late PET in this context.

Methods

The study population comprised 32 prostate cancer patients with early evidence of relapse after initial radiotherapy (group A) or radical surgery (group B). The median PSA of group A (n=17) patients was 6 ng/ml (range 2.6–30.2) while that of group B (n=15) was 0.4 ng/ml (range 0.08–4.8). Pelvic-abdominal-thoracic PET was started 2 min after injection of 11C-acetate and evaluated after fusion with CT.

Results

Group A: Taking a SUVmax≥2 as the cut-off, PET showed local recurrences in 14/17 patients and two equivocal results. Distant disease was observed in six patients and an equivocal result was obtained in one. Endorectal MRI was positive in 12/12 patients. Biopsy confirmed local recurrence in six of six (100%) patients. PET was positive in five of the six patients with biopsy-proven recurrences, the result in the remaining patient being equivocal. Group B: Among the 15 patients, visual interpretation was positive for local recurrences in five patients and equivocal in four. One obturator lymph node was positive. Endorectal MRI was positive in 11/15 patients and equivocal in two. Positional correlation of positive/equivocal results on PET and endorectal MRI was observed in seven of nine patients. PSA decreased significantly after salvage radiotherapy in 8/14 patients, providing strong evidence for local recurrence. PET of the eight patients responding to RT was positive in three and equivocal in two.

Conclusion

11C-acetate PET was found to be valuable in the early evaluation of prostate cancer relapse. Optimising scanning time and use of modern PET-CT equipment might allow further improvement.

Keywords

11C-acetatePETProstate cancer relapsePSA

Copyright information

© Springer-Verlag 2006